AUSTIN, TX / ACCESS Newswire / August 13, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress under its new leadership team.

Q2 2025 Net Revenue of $127.3 million and Adjusted EBITDA 1  of $28.6 million Tenth straight quarter of positive operating cash flow with $17.8 million generated Fully retired $60 million term loan via strategic refinancing Robust cash position of $95.3 million at quarter end NEW YORK , Aug. 7, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today reported its financial results for the quarter ended June 30, 2025 ("Q2 2025"). Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and all currency is in U.S. dollars.

AUSTIN, TX / ACCESS Newswire / July 15, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Jane Pine Wood to the Board of Directors, effective July 11, 2025. "We are pleased to welcome Jane Pine Wood to the Board of Directors," said Jack Fraser, Chairman of the Board of Directors of Aspira Women's Health.

NEW YORK , July 10, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Thursday, August 7, 2025, at 5:00 PM ET following the release of its second quarter 2025 financial results.  The earnings conference call may be accessed by dialing 1-888-699-1199.

Aspira and Dorsata Launch Clinical Workflow Tool for Adnexal Masses, Now Live for All Dorsata Clients, Adnexal Mass Evidence-Based Decision Support AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 17, 2025 / Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider workflow platform for women's health, announced today the official launch of a new adnexal mass clinical decision support module in partnership with Dorsata, a leading women's health electronic health record software solutions company. Dorsata's platform is currently used by more than 700 women's health providers across over 300 practice sites in 20 states, helping clinicians standardize care delivery and improve outcomes through guided clinical workflows and real-time decision support for over 1.5 million patients each year.

AUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team.

First Quarter 2025 Net Revenue of $128.0 million and Adjusted EBITDA 1  of $27.0 million Generated Positive Cash from Operations of $5.9 million, the Ninth Consecutive Quarter of Positive Operating Cash Flow Company Ended Q1 2025 with $100.0 million of Cash and Cash Equivalents NEW YORK , May 12, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the quarter ended March 31, 2025 ("Q1 2025"). Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP") and all currency is in U.S. dollars.

NEW YORK , April 28, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Monday, May 12, 2025, at 5:00 PM ET following the release of its first quarter 2025 financial results.  The earnings conference call may be accessed by dialing 1-888-699-1199.

SHELTON, CT / ACCESS Newswire / April 17, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the Company previously traded. About Aspira Women's Health Inc.  Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.

SHELTON, CT / ACCESS Newswire / April 16, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market.